BIOSIMILARS IN INFLAMMATORY BOWEL DISEASES: an important moment for Brazilian gastroenterologists
ABSTRACT Biosimilars are not generic drugs. These are more complex medications than small molecules, with identical chemical structures of monoclonal antibodies that lost their patency over time. Besides identical to the original product at the end, the process of achieving its final forms differs f...
Main Authors: | Fábio Vieira TEIXEIRA, Paulo Gustavo KOTZE, Aderson Omar Mourão Cintra DAMIÃO, Sender Jankiel MISZPUTEN |
---|---|
Format: | Article |
Language: | English |
Published: |
Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologia (IBEPEGE)
2015-03-01
|
Series: | Arquivos de Gastroenterologia |
Subjects: | |
Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-28032015000100016&lng=en&tlng=en |
Similar Items
-
ANVISA APPROVES THE FIRST BIOSIMILAR MONOCLONAL ANTIBODY BASED ON COMPARABILITY IN BRAZIL
by: Fábio Vieira TEIXEIRA, et al. -
RESEARCH IN INFLAMMATORY BOWEL DISEASES IN LATIN AMERICA: a challenge ahead
by: Paulo Gustavo KOTZE
Published: (2014-12-01) -
BIOLOGICAL THERAPY PENETRATION FOR INFLAMMATORY BOWEL DISEASE IN LATIN AMERICA: CURRENT STATUS AND FUTURE CHALLENGES
by: Abel Botelho QUARESMA, et al. -
THE ONSET OF CLINICAL MANIFESTATIONS IN INFLAMMATORY BOWEL DISEASE PATIENTS
by: Viviane Gomes NÓBREGA, et al. -
ADALIMUMAB FOR ULCERATIVE COLITIS: RESULTS OF A BRAZILIAN MULTICENTER OBSERVATIONAL STUDY
by: Patrícia ZACHARIAS, et al.
Published: (2017-10-01)